Yang‐Xin Fu

This study develops a functional screening method to identify TCR-like antibodies targeting tumor neoantigens, demonstrating their anti-tumor efficacy in vitro and in vivo.

A 'shock-and-lock' nanoparticle agonist activates STING in type 1 conventional dendritic cells to enhance antitumor immunity with associated biomarkers.

The paper identifies cancer-associated T cells using TCR repertoire and gene expression data, revealing novel regulators and antigens with potential for immune monitoring and immunotherapy.